2018 FDA Tides Harvest
KRISP, School of Laboratory of Medicine and Medical Science, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa
School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa
CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine and Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Received: 12 March 2019 / Revised: 3 April 2019 / Accepted: 3 April 2019 / Published: 5 April 2019
PDF [877 KB, uploaded 5 April 2019]
In 2018, the United States Food and Drug Administration (FDA) approved a total of 59 new drugs, three of them (5%) are TIDES (or also, -tides), two oligonucleotides and one peptide. Herein, the three TIDES approved are analyzed in terms of medical target, mode of action, chemical structure, and economics.
This is an open access article distributed under the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Al Shaer, D.; Al Musaimi, O.; Albericio, F.; de la Torre, B.G. 2018 FDA Tides Harvest. Pharmaceuticals 2019, 12, 52.
Al Shaer D, Al Musaimi O, Albericio F, de la Torre BG. 2018 FDA Tides Harvest. Pharmaceuticals. 2019; 12(2):52.
Al Shaer, Danah; Al Musaimi, Othman; Albericio, Fernando; de la Torre, Beatriz G. 2019. "2018 FDA Tides Harvest." Pharmaceuticals 12, no. 2: 52.
Show more citation formats
Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
[Return to top]
For more information on the journal statistics, click here
Multiple requests from the same IP address are counted as one view.